TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05593302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Art Therapy (TFAT)
Description: Individual Trauma Focused Art Therapy (TFAT) consisting of 10 sessions. Each session lasts 60 minutes. Sessions are aimed at trauma recovery using visual art therapy. The sessions cover an introduction, making pieces of artwork, and reflection. Three phases can be distinguished:~Phase 1: 'stabilization and symptom reduction', i.e. exploring traumatic and positive memories, imagining a lifecourse, and expressing a safe haven (4 sessions).~Phase 2:'uttering and expressing memories', i.e. expressing chosen memories by making 5 pieces of artwork. Materials that can be used include clay, paint, graphite pencil or crayons and if needed with support of imagination using relevant photographs or objects (5 sessions).~Phase 3: 'integration and meaning attribution', i.e. ordering and assembling of the 5 pieces of artwork. Patients are asked to appraise the memories in the here-and-now present (c.f. mindfulness-based cognitive therapy) (1 session).
Study: NCT04615130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Rehabilitation, exercise training
Study: NCT05806944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS followed by Sham TMS
Description: double blinded crossover schedule in which participants will undergo TMS and assessment in one visit, followed by sham-TMS and assessment the next visit.
Study: NCT03443622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-43 Oral Solution
Description: SC-43 Oral Solution has drug substance of 1-\[4-chloro-3(trifluoromethyl)phenyl-3-\[3-(4-cyanophenoxy)\] urea, or SC-43. SC-43 inhibits tumor growth through the activation of Src homology region 2 domain-containing phosphatase-1 (SHP-1) and the repression of p-STAT3 signalings. As a result of STAT3 inhibition by SC-43 treatment, decreased cell viability and enhanced apoptosis have been observed in cancer cells. The anti-tumor activity of SC-43 was also investigated in a variety of xenograft tumor models. Administration of SC-43 provides the tumor-bearing animals survival benefits, including the reduction of tumor volume and prolonged lifespan. SC-43 has been proposed to be evaluated as an anticancer therapeutic in in subjects with refractory solid tumors in the phase I trial.
Study: NCT05083936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FET
Description: Imaging evaluation using LAT1/4F2hc substrate overexpressed in brain tumor
Study: NCT05768230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levosimendan
Description: Levosimendan 12.5mg was injected intravenously in a 5% glucose injection 50ml configuration at a rate of 2ml/h for 24 hours.The injection was performed at a constant rate of 2ml/h. If there was no significant hypotension or tachycardia, the injection was completed within 24h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% glucose injection
Description: 5% glucose injection 50ml configuration at a rate of 2ml/h for 24 hours.The injection was performed at a constant rate of 2ml/h. If there was no significant hypotension or tachycardia, the injection was completed within 24h
Study: NCT05840224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-4528
Description: Administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-4528
Description: Administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS-4528
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered intravenously.
Study: NCT06143345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training and eucaloric diet
Description: Intervention participants will complete 24 supervised high-intensity interval training (HIIT) sessions over 8 weeks, with 3 sessions per week on alternate days. Each HIIT session will consist of a 5-minute warm-up, followed by an interval-based workout phase that includes steady up-tempo cadences, sprints, and climbs, interspersed with recovery periods. The session will conclude with a 5-minute cooldown. The workout sessions will initially last 20 minutes and will progressively increase in time based on participants\&amp;#39; tolerance and instructor recommendations. Intensity will start at 75% of estimated maximal heart rate reserve and will increase by 5% weekly, as tolerated and/or deemed necessary by the instructor, over the 8-week intervention period. Participants will receive instructions to maintain a eucaloric diet throughout the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No intense physical activity and eucaloric diet
Description: Control participants will be instructed to refrain from engaging in intense physical activities during the study period. They will also receive instructions to maintain a eucaloric diet throughout the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring (CGM) (Dexcom G6 Pro CGM sensor)
Description: The continuous glucose monitoring (CGM) system comprises a sensor, a transmitter, and a receiver. The sensor measures interstitial fluid glucose levels every 5 minutes, and the transmitter wirelessly sends this glucose data to the receiver. Both intervention and control participants will wear the CGM device in a blinded mode for 10 days before starting the intervention, throughout the 8-week intervention period, and for 10 days post-intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) (Dexcom G6 Pro CGM sensor)
Description: The continuous glucose monitoring (CGM) system comprises a sensor, a transmitter, and a receiver. The sensor measures interstitial fluid glucose levels every 5 minutes, and the transmitter wirelessly sends this glucose data to the receiver. Both intervention and control participants will wear the CGM device in a blinded mode for 10 days before starting the intervention, throughout the 8-week intervention period, and for 10 days post-intervention.
Study: NCT04834505

Intervention type: OTHER
Intervention: Diagnostic imaging modalities for validation sample
Description: Endoscopic ultrasound and other imaging modalities such as CT, MRI, or PET-CT are performed.

Intervention type: OTHER
Intervention: EUS for derivation sample
Description: Endoscopic ultrasound was performed.
Study: NCT05806944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS followed by Sham TMS
Description: double blinded crossover schedule in which participants will undergo TMS and assessment in one visit, followed by sham-TMS and assessment the next visit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham TMS followed by TMS
Description: double blinded crossover schedule in which participants will undergo sham TMS and assessment in one visit, followed by TMS and assessment the next visit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham TMS followed by TMS
Description: double blinded crossover schedule in which participants will undergo sham TMS and assessment in one visit, followed by TMS and assessment the next visit.
Study: NCT04717362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natesto Nasal Product
Description: Nasally administered exogenous 4.5% testosterone gel, administered from a non-pressurized, manual pump dispenser equipped with a specialized nasal applicator which administers 125uL (5.5mg of testosterone).
Study: NCT05887271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low calorie meal replacement plan
Description: Meal replacement diet containing \~850 kcal/day (40% protein, 50% carbohydrate, 10% fat) supplied by Counterweight® (www.counterweight.org).The meal replacement plan will comprise of 3-4 meal packs/day (to equate to 850 kcal) with sweet and savoury options, and an allowance of 100ml semi-skimmed milk or a non-dairy alternative.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy
Description: CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue. Cardiac 31P magnetic resonance spectroscopy imaging to assess cardiac muscle energetics according to a standardised operating procedure

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy
Description: CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue. Cardiac 31P magnetic resonance spectroscopy imaging to assess cardiac muscle energetics according to a standardised operating procedure
Study: NCT04995406

Intervention type: DIAGNOSTIC_TEST
Intervention: ISIT-TB prototype
Description: Diagnostic assay able to identify active tuberculosis using a patient blood sample processed on an automatized system within an hour

Intervention type: DIAGNOSTIC_TEST
Intervention: ISIT-TB prototype
Description: Diagnostic assay able to identify active tuberculosis using a patient blood sample processed on an automatized system within an hour

Intervention type: DIAGNOSTIC_TEST
Intervention: ISIT-TB prototype
Description: Diagnostic assay able to identify active tuberculosis using a patient blood sample processed on an automatized system within an hour

Intervention type: DIAGNOSTIC_TEST
Intervention: ISIT-TB prototype
Description: Diagnostic assay able to identify active tuberculosis using a patient blood sample processed on an automatized system within an hour
Study: NCT04148716

Intervention type: PROCEDURE
Intervention: additional biopsies
Description: additional biopsies during a fibroscopy planned in the care
Study: NCT06576960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nano silver fluoride varnish and tri calcium phosphate varnish
Description: Fluoride varnishes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nano silver fluoride varnish and tri calcium phosphate varnish
Description: Fluoride varnishes
Study: NCT06382194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: The intervention is a newly developed decision aid designed to guide decisions about storage of firearms among older gun owners with early dementia and/or depression.
Study: NCT05404646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic mobility exercises with conventional physical therapy for cervical radiculopathy
Description: Thoracic mobility exercises These techniques include mobilization, manipulation and glides to check and treat the joints. Here, these techniques will be used to mobilize the thoracic spine. In this treatment mobility exercises (Unilateral posterior anterior, Central posterior anterior and transverse glides) + hot pack (10 min) + neck stretching (neck flexors, extensors, side benders) + cervical Traction will be given to patient. A total session time will be 45 min and thrice a week on alternate days for three weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic stretching exercises with conventional physical therapy for cervical radiculopathy
Description: Thoracic stretching exercises Thoracic stretching exercises. Thoracic stretching exercises are used to correct the musculature of thoracic region. In this treatment group stretching exercises (passive stretches and therapist facilitated exercises) +hot pack (10 min) +neck stretching (neck flexors, extensors, side benders) + tractions will be given to patient. A total of 45 min session thrice a week on alternate days for three weeks will be given. Only the eligible patients who fulfil the inclusion criteria will be included in the study.
Study: NCT06014138

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Standard care, propofol sedation - 2 hour periods of observation before and after inhaled volatile sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: Inhaled volatile sedation for 6 hours - 2 hours wash in / wash out, followed by 4 hours of observations
Study: NCT04750265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic assisted early mobilization
Description: Robotic assisted early mobilization Robotic assisted early mobilization started within 72 hours of ICU admission.
Study: NCT05127213

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intragastric balloon system
Description: Intragastric balloon system (PA450) developed and produced by Changzhou Zhishan Medical Technology Co., Ltd. It is a swallowable capsule intragastric balloon.The degradable material on the intragastric balloon can be degraded naturally, and the balloon is naturally discharged from the body through the gastrointestinal tract

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Description: Sleeve gastrectomy is the use of laparoscopy to cut out the greater curvature of the stomach, mainly for weight loss.
Study: NCT06437717

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: application of different topical nasal solutions
Description: each group receives a type of nasal solution to detect if there is a difference in the outcomes in chronic rhinosinusitis patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: application of different topical nasal solutions
Description: each group receives a type of nasal solution to detect if there is a difference in the outcomes in chronic rhinosinusitis patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: application of different topical nasal solutions
Description: each group receives a type of nasal solution to detect if there is a difference in the outcomes in chronic rhinosinusitis patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: application of different topical nasal solutions
Description: each group receives a type of nasal solution to detect if there is a difference in the outcomes in chronic rhinosinusitis patients
Study: NCT06208085

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Avocado
Description: Intervention arm
Study: NCT04953910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASTX727
Description: Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
Study: NCT06565611

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bremelanotide
Description: bremelanotide (BMT) sterile aqueous solution for subcutaneous injection, provided as autoinjectors containing 0.3 mL volume

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bremelanotide
Description: bremelanotide (BMT) sterile aqueous solution for subcutaneous injection, provided as autoinjectors containing 0.3 mL volume

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tirzepatide
Description: tirzepatide (GLP-1/GIP) will be provided in its commercial form for SC injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tirzepatide
Description: tirzepatide (GLP-1/GIP) will be provided in its commercial form for SC injection.
Study: NCT06400537

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A-319
Description: A-319 will be dosed according to the assigned group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A-319
Description: A-319 will be dosed according to the assigned group.
Study: NCT06626373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elderberry Juice
Description: Participants will consume elderberry juice 1-week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beverage
Description: Participants will consume placebo beverage twice/day for 1-week.
Study: NCT06624540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: This is a pre- and post- quasi-experimental study.
Description: We will use new equipment and implement EBP (VAP management) for patients by trained nurses (Study 2) and check the outcome of the patients. We will compare our study 1 findings for this study as historical data.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education with EBP
Description: Study 2: Nurse's EBP training ( VAP management), 2 hours lecture and 3 hours skill training for total 4 times in 1 month.~Study 3: Introduce new equipment necessary for EBP implementation for VAP management, and EBP-trained nurses implementation for VAP management.
Study: NCT06624774

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prehabilitation
Description: The structured exercise sessions will be conducted in a homebased setting, consisting of 8 resistance exercises (RE). The 8 RE's will include 4 upper body and 4 lower body exercises (Sit to stand, chest press, heel raises, bicep curls, leg abduction, tricep kickbacks, lunges, mid row). This is adapted from an existing home-based trial in cardiac patients. In addition, the structured exercise programme will include a walking programme. Participants will receive a Fitbit charge 5 activity monitor. Additionally, participants will conduct daily IMT via a Powerbreathe medic plus device. Participants will conduct 6 sets of 6 breaths at 50% of peak inspiratory pressure that has been measured at baseline. Education will be delivered via pre-recorded videos or in person
Study: NCT06625619

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT06624891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perioperative fluid responsiveness with the Pleth variability index
Description: Perioperative fluid challenge and responsiveness will be based on monitoring the pleth variability index. In fact, volemia will be estimated with the PVI.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: perioperative fluid responsiveness with delta PP
Description: fluid challenge and responsiveness during intervention will be based on monitoring delta PP.
Study: NCT06625034

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon Beam Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Beam Radiation Therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy Treatment Planning and Simulation
Description: Receive human-driven treatment planning

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy Treatment Planning and Simulation
Description: Receive RapidPlan treatment planning
Study: NCT04814654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHALO! 2.0
Description: The components of the intervention are:~Contents of digital-media (sent twice/week for 12 weeks) on the following topics: HIV testing, prevention, treatment, linkage-to-care; Personalized digital coupon for free testing; Webpage listing testing/ care sites; access to online outreach workers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention-matched control (AMC)
Description: The components of the intervention are:~Contents of digital-media (sent twice/week for 12 weeks) only related to general health information; Personalized digital coupon for free testing; Webpage listing testing/ care sites; access to online outreach workers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital coupon only (DCO)
Description: The components of the intervention are:~Digital coupon for free HIV testing; Webpage listing testing/ care sites; access to online outreach workers.